PDCD1 and neoplasm: In contrast, inhibition of SPRK1—an upstream regulator of SRSF1 phosphorylation—shifts PD-1 splicing toward ΔEx3 PD-1, reducing surface PD-1 and enhancing anti-tumor immunity [95].